Advertisement

Advertisement

KTTA Stock Latest News

Pasithea Therapeutics announces updated data from PAS-004 trial

The FlyPasithea Therapeutics announces updated data from PAS-004 trial

Pasithea Therapeutics announces amendments to PAS-004 clinical study

PremiumThe Fly

Pasithea Therapeutics announces amendments to PAS-004 clinical study

1M ago

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

PremiumThe Fly

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

2M ago

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

PremiumThe Fly

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

2M ago

Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

PremiumRatings

Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

2M ago

Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives

PremiumCompany AnnouncementsPasithea Therapeutics Appoints New CMO, Updates Equity Incentives

3M ago

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

The Fly

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

3M ago

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

The Fly

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

3M ago

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

PremiumCompany Announcements

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

5M ago

Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

PremiumCompany Announcements

Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

6M ago

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

PremiumRatings

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

6M ago

Pasithea Therapeutics provides updated timeline on PAS-004 programs

PremiumThe Fly

Pasithea Therapeutics provides updated timeline on PAS-004 programs

6M ago

Pasithea Therapeutics Regains Nasdaq Compliance

PremiumCompany AnnouncementsPasithea Therapeutics Regains Nasdaq Compliance

7M ago

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

The Fly

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

8M ago

3 Penny Stocks to Watch Now, 12/2/25

Market News

3 Penny Stocks to Watch Now, 12/2/25

8M ago

Pasithea Therapeutics Completes $60M Public Offering

PremiumCompany Announcements

Pasithea Therapeutics Completes $60M Public Offering

8M ago

Pasithea Therapeutics prices 80M shares at 75c in public offering

PremiumThe Fly

Pasithea Therapeutics prices 80M shares at 75c in public offering

8M ago

3 Penny Stocks to Watch Now, 11/27/25

PremiumMarket News

3 Penny Stocks to Watch Now, 11/27/25

8M ago

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

PremiumCompany Announcements

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

8M ago

Pasithea Therapeutics announces $1M award by ALS Association

PremiumThe FlyPasithea Therapeutics announces $1M award by ALS Association

8M ago

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

The Fly

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

8M ago

Pasithea says tablet PK exposure increases proprtionally with dose increase

The Fly

Pasithea says tablet PK exposure increases proprtionally with dose increase

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >